Asure Software Inc. (NASDAQ:ASUR) Spikes After Record Q3

Asure Software Inc. (NASDAQ:ASUR)

Asure Software Inc. (NASDAQ:ASUR) shares gained 12.97% after the Austin-based maker of human capital management programs reported record revenue for the third quarter. The achievement was driven by continued growth across the entire business as the company continued to integrate multiple acquisitions made this year.

Asure Software Inc. (NASDAQ:ASUR)

ASUR Stock Performance

The better-than-expected third quarter financial results helped strengthen the stock’s sentiments on Wall Street. Investors’ confidence appears to be slowly building up, the stock having come under pressure in recent months.

For the full year, Asure Software Inc. (NASDAQ:ASUR) is up by more than 40%. The stock faces immediate resistance at the $13.50 mark, above which it could make a push for its 52-week high of $16.03 a share.

Asure’s Q3 Financial Results

Revenue for the three months ended September 30, 2017, increased 65% to $15.5 million. Cloud revenue was up 97%, as hardware revenue increased 48% compared to the third quarter of 2016. Gross margin came in at $12.1 million or 78.1% of total revenue, representing a 64% increase from $7.4 million reported last year.

Asure Software Inc. (NASDAQ:ASUR) reported a net income per share of $0.15 a share compared to a non-GAAP net income per share of $0.22 a share reported last year. The Chief Financial Officer, Kelyn Brannon, attributes the better than expected Q3 financial results to the execution of a cloud sales initiative that helped produce solid gross margins and recurring revenue.

“Additionally, our strong cash position as well as our investments in infrastructure and processes has increased the operating leverage of our business model. Overall, our results in the third quarter reflect the increasing demand for our solutions as well as the cost and operational synergies from the strategic acquisitions we have completed this year,” said Mr. Brannon.

For the full year, Asure Software Inc. (NASDAQ:ASUR) expects revenue of between $54.25 million and $56.25 million. Excluding one-time items, Non-GAAP EBITDA should range between $12.2 million and $13.5 million. The company is also projecting Non-GAAP net loss per share of between $0.06 and $0.02 a share.

Asure Software is projecting revenues of $70 million for 2018 as it moves to integrate already completed acquisitions. The company also plans to carry out multiple ‘tuck-in” acquisitions of service bureaus, which could drive further growth.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ASUR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Aptose Biosciences Inc (NASDAQ:APTO)

New High for Aptose Biosciences Inc (NASDAQ:APTO)

Aptose Biosciences Inc (NASDAQ:APTO)

Aptose Biosciences Inc (NASDAQ:APTO) shares have hit a new 52-week high, are up over 17%, and trading around the $2 handle in mid-afternoon trading. Volume is heavy for the biotech’s shares as they are trading about seven times their daily average.

Aptose Biosciences Inc (NASDAQ:APTO)

Aptose Biosciences Inc (NASDAQ:APTO) is scheduled to be releasing their Q3 2017 earnings report tomorrow, November 14, 2017, after the close of trading. According to Zacks Investment Research, the consensus of analysts are expecting an EPS loss of (-$0.13) per share.

Canadian-based Aptose Biosciences Inc (NASDAQ:APTO) is a clinical-stage biotechnology company committed that develops personalized therapies designed to address unmet medical needs in cancer patients. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer treatment. The company’s pipeline of small molecule cancer therapeutics includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

APTO Stock Performance

Shareholders of Aptose Biosciences Inc (NASDAQ:APTO) have experienced a good year. Year-to-date, APTO stock is up over 22%, and for the year the gain is an even more impressive 65%. Analysts have given APTO stock a consensus, one-year price target of $3.15. The stock’s 52-week low was established last April at a price of $0.78. Today’s price action, should it hold, will establish a new 52-week high – besting the old mark of $1.79. Given the strong upward momentum of the stock, it is not surprising that the shares have a Relative Strength score of 77 – a level that most traders consider to be a sign of an “overbought” condition.

Aptose Biosciences Inc (NASDAQ:APTO) has no reported sales. Accordingly, their earnings have been negative since 2012. In the past three years, the per share losses have expanded. In 2014 the per share loss was (-$0.53), followed the next year by (-$0.97), and (-$1.15) for 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $APTO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Capricor Therapeutics Inc (NASDAQ:CAPR)

Traders Loving Capricor Therapeutics Inc (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR) shares gapped up this morning and have gained over 20% from their Friday closing price on ten times their average daily volume. CAPR stock opened at $2.65, $0.38 above Friday’s close, and moved above the $3 handle within ten minutes. Sellers then came in and pushed the price down to $2.80 before the shares resumed their upward move. At the time of the writing, 10:15 AM EST, CAPR stock is trading around the $3 once again.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company discovers, develops, and commercializes biological therapeutics for the treatment of rare disorders. Capricor’s lead drug candidate is, CAP-1002 – an “off-the-shelf” cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

On November 8, 2017, Beverly Hills, CA-based Capricor Therapeutics, Inc. (NASDAQ:CAPR) reported a Q3 2017 loss of (-$2.7). or (-$0.12) per share, on adjusted revenues of $313,000. The loss beat analyst expectations that forecasted a loss of (-$0.19) per share. The biotech firm also bested expectations in Q2 when actual earnings beat estimates by 11%.

CAPR Stock Performance

At the beginning of 2012 CAPR stock was trading above $20 before it went into a steady slide. Over the past year CAPR stock has experienced a wide range in its price. Its 52-week low is $0.63 but its 52-week high is $4.25.

Shareholders of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have lagged the market as the stock is down 7% year-to-date. However, in the past quarter, shares have risen over 114%. That strong gain is reflected in CAPR’s Relative Strength Index score of 68 – just below the level of 70 which many traders believe to be the threshold figure for an “oversold” condition.

Losses have plagued the company since 2012 when they posted a EPS of (-$0.21), followed by annual EPS losses of (-$0.85), (-$0.53), (-$0.81), and, for 2016, (-$1.01). Sales were on a positive slope from 2013 when it reported a figure of $500,000. By 2015 that number grew to $5.5 million, but declined in 2016 to $4 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CAPR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

FuelCell Energy Inc. (NASDAQ:FCEL)

FuelCell Energy Inc. (NASDAQ:FCEL) Short Interest Drops

FuelCell Energy Inc. (NASDAQ:FCEL)

FuelCell Energy Inc. (NASDAQ:FCEL) shares gained 4.52% in Friday’s trading session as short interest on the stock continued to drop. Over the past two weeks, short interest has dropped by 3.3% and currently accounts for 7.2% of the company’s total float.

FuelCell Energy Inc. (NASDAQ:FCEL)

Fuel Cell Technology

FuelCell Energy Inc. (NASDAQ:FCEL) has been on an impressive run – since June it has gained more than 100% in market value. However, for the full year, the stock is up by 15%. The stock is currently trading in an uptrend.

Growth in popularity of the company’s fuel cell technology appears to have strengthened investors’ confidence in the company’s long-term prospects. The technology utilizes a chemical reaction to convert a fuel source to electricity. Given its benefits and the fact that it is eco-friendly, the U.S Defense Department has started to use the technology.

General Motors has started working with the U.S army to develop fuel cell electric vehicles as the race to reduce dependence on conventional fuel gathers momentum. The rise in popularity of this technology has resulted in fuel cell producers like FuelCell attracting big contracts from customers across various sectors.

FuelCell Energy Inc. (NASDAQ:FCEL) has since entered into a power purchase agreement with the Connecticut Municipal Electric Energy Cooperative. The agreement is for the supply of power to the U.S Navy Submarine Base in Groton. The 7.4MW clean power is to be generated from the company’s two SureSource 400TM power plants.

The power project will ensure the U.S Navy has long-term cost-effective power for powering critical infrastructure. The fuel cell plants are also to be configured for grid-independent operations.

“Our fuel cell solutions are compelling as their predictable and clean power generation profile meets resiliency and environmental goals simultaneously. Additionally, this project is structured so that the U.S. Navy enjoys the many benefits of clean on-site power generation while continuing to work with its local and trusted utility under a pay-as-power-is-produced model,” said CEO Chip Bottone.

SureSource Certification

Separately, FuelCell Energy Inc. (NASDAQ:FCEL)’s SureSource 1500 fuel cell power plant operating on Anaerobic Digester Gas has received an important certification. The California Air Resources Board’s certification acknowledges the clean air profile of the solution, in facilitating air permitting process which reduces costs.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $FCEL and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Drops As Earnings Beat

Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) fell 13.93% after the company reported on its Phase 1 clinical data for IPI-549, an oral selective phosphoinositide-3-kinase-gamma targeting immune-suppressive tumor macrophages. Trial results indicate that the candidate drug was well tolerated and clinically active.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI)

Clinical Trial Results

The sell-off on Infinity Pharmaceuticals Inc. (NASDAQ:INFI) stock comes as a surprise, given that the biopharmaceutical company is fresh from posting a narrower than expected third-quarter net loss. However, the stock is still trading in an uptrend despite coming under pressure in recent trading sessions. The stock is up by more than 60% for the year, as it continues to outperform the overall industry.

The positive IPI-549 and Q3 financial results should affect the stock’s direction of trade heading into the end of the year.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) is evaluating IPI-549 as a monotherapy and in combination with Opdivo in patients with advanced tumors.

There is a significant need for better treatment options to take care of patients who do not respond to existing immunotherapies.

“In particular, patients with mesothelioma and adrenocortical carcinoma have limited effective treatment options, and our early evidence of activity suggests the potential for IPI-549 to improve outcomes for these patients,” said CEO Adeline Perkins.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) is to report data from a monotherapy expansion component of the study in the first half of 2018. The company also plans to report data from a combination expansion component in the first half of next year.

Infinity Q3 Financial Results

For the three months ended September 30, 2017, Infinity Pharmaceuticals posted a net loss of (-$7.1) million or (-$0.14) million, compared to a net loss of (-$19.5) million reported last year. Revenue in the quarter totaled $6 million related to amounts due from Verastem for the DUO study.

Restructuring activities in the quarter resulted in research and development expenses dropping to $9.3 million, from $12.8 million reported last year. Infinity Pharmaceuticals exited the quarter with cash and cash equivalent of $55.6 million compared to $66.2 million as of June 30, 2016. General and Administrative expenses also dropped because of the restructuring activities to $4.5 million from $7.1 million a year ago.

For the full year, the biopharmaceutical company is projecting a net loss of between $40 million and $50 million. Cash and cash equivalents should range from $40 million and $50 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $INFI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Avid Technology, Inc. (NASDAQ:AVID)

Avid Technology, Inc. (NASDAQ:AVID) Q3 Earnings Beat Estimates

Avid Technology, Inc. (NASDAQ:AVID)

Shares of Avid Technology, Inc. (NASDAQ:AVID) gained 26.24% after the global media technology company reported better than expected Q3 2017 financial results. Revenues and bookings exceeded guidance in the quarter. Strong improvement in adjusted EBITDA allowed the company to post a fourth consecutive quarter of positive cash flow.

Avid Technology, Inc. (NASDAQ:AVID)

AVID Investors Reaction

Investors reacted to the stellar financial results by pushing the stock from this year’s lows to $5.10 a share. The stock is up by more than 10% for the year. Avid Technology, Inc. (NASDAQ:AVID) faces resistance at the $5.50 mark above which it could make a to this year’s highs of $6 a share.

Renewed investor interest in the stock is as a result of the company exceeding guidance in all its key metrics. According to Chief Executive Officer, Louis Hernandez, Jr., completion of transformation should allow Avid technology to drive profitable growth as well as increase revenue visibility and cash flow.

AVID Q3 Results

For the three months ended September 30, 2017, Avid technology bookings came above the upper end of guidance at $102.8 million. Constant currency bookings totaled $107.9 million which were in line with guidance. GAAP Revenue was $105.3 million above the upper end of guidance. Gross margin came in at 57.3%.

Net income in the quarter came in at $72,000 as adjusted free cash flow came in at $0.5 million at the upper end of the guidance. Adjusted free cash flow for the first nine months rose to $55.7 million,

According to the Chief Executive Officer, customers ranging from the largest media enterprise continue to adopt Avid Technology, Inc. (NASDAQ:AVID)’s innovative solutions.

“With our cloud-enabling MediaCentral platform, enterprises are unlocking greater strategic value from their Avid partnership as we help them to achieve new economies of scale while they work to engage audiences on any device with increasing amounts of content,” said Mr. Hernandez.

Q4 Outlook

During the quarter, Avid Technology, Inc. (NASDAQ:AVID) signed several multi-year enterprise deals with large customers, including Viacom and NHK. Total licenses for the MediaCentral platform increased 27% year-over-year to 51,000. Direct digital bookings with individual creative professionals increased 35% year-over-year.

For the fourth quarter Avid Technology, Inc. (NASDAQ:AVID) expects bookings to range between $118 and $132 million. Revenue, on the other hand, should range between $103 and $113 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AVID and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Q3 Net Loss Narrows

BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) fell 5.36% after reporting a net loss of (-$12) million for the three months ended September 30, 2017. However, the results exceeded Wall Street expectations as revenue increased 29% compared to the second quarter.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

Management remarks

The stock is currently trading at a key support level of $2.65, below which it could drop to the next support level at $2.20. BioDelivery Sciences has come under pressure in recent weeks after touching highs of $3.40 a share. Observers are keen to see if the third quarter financial results is the catalyst that will help push the stock up.

According to the Chief Executive Officer, Mark Sirgo, the solid performance in the quarter was because of the strong sales momentum behind lead product BELBUCA.

“Our solid performance in the third quarter continued the encouraging trend we have seen with BELBUCA, as we achieved prescription growth of 15% over the second quarter. The favorable trend continued into October as BELBUCA monthly total prescriptions reached an all-time high in excess of 8,000 based on preliminary sales data,” said Mr. BELBUCA.

The executive expects continued growth of BELBUCA going forward due to a new sales strategy and improved managed care involving Medicare. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has also completed an important licensing agreement with Purdue Pharma for BELBUCA.

Q3 Financial Results

Net Revenue for the three months ended September 30, 2017, came in at $11.3 million, up from $3.6 million reported in the third quarter of 2016. BELBUCA and BUNAVAIL revenue totaled $6.4 million and $1.7 million respectively. Net revenue for the first nine months of the year totaled $49.5 million compared to $11.6 million in the same period last year.

Total operating expenses for the quarter was $16.9 million compared to $16.5 million reported last year. Net loss decreased to (-$12 million) or (-$0.21) a share compared to a net loss of (-$16) million or (-$0.30) a share, reported last year. The decrease in net loss was primarily attributed to net profitability from the reacquisition of BELBUCA early in the year.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has cash and cash equivalents of $19.7 million compared to $27.5 million as of June 30, 2017. During the quarter, the company met the financial requirements needed to access the next $15 million tranche in its loan agreement with CRG.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BDSI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Zosano Pharma Corp (NASDAQ:ZSAN)

Zosano Pharma Corp (NASDAQ:ZSAN) Q3 Net Loss Widens

Zosano Pharma Corp (NASDAQ:ZSAN)

Zosano Pharma Corp (NASDAQ:ZSAN) shares gained 3.70% after the clinical stage biopharmaceutical company reported financial results and an operational update for Q3 2017. The unveiling of the financial results comes a day after the company initiated long-term safety study of zolmitriptan in migraine patients.

Zosano Pharma Corp (NASDAQ:ZSAN)

Zosano’s Net Loss

Zosano generated a net loss of (-$7.9) million or (-$0.20) a share in the third quarter, a slight increase from a net loss of (-$7.4) million, or (-$0.52) a share, reported last year. It awaits to be seen how investors will react to the wider than expected net loss as the stock continues to trade in a downtrend.

The stock has shed more than 70% in market value since March an underperformance that has plunged it to this year’s lows. Zosano Pharma Corp (NASDAQ:ZSAN) is currently trading near its 52-week low of $0.48 and in dire need of new catalyst if it’s to bounce back.

Research and development expenses in the quarter increased to $5.7 million from $5.1 million reported in Q3 of 2016. General and Administrative expenses remained unchanged at $2 million. Zosano exited the quarter with cash and cash equivalent of $19.8 million debt of $8.2 million and 39.2 million common shares outstanding.

During the quarter, the clinical stage biopharmaceutical company made important strides in the development of its pipeline of drugs. In September, the company presented data from Phase 2/3 ZOTRIP study evaluating M207 as a novel treatment for a migraine.

“The company continues to execute on our path to an NDA, including the initiation of our long-term safety study on November 7 and the continued scale up of manufacturing to support potential commercialization, pending approval of M207 by the FDA,” said CEO, John Walker.

Share Purchase Agreement

Separately, Zosano Pharma Corp (NASDAQ:ZSAN) has entered into a common share purchase agreement with Chicago-based institutional investor, Lincoln Park Capital Fund LLC. Pursuant to the approval of the SEC, the company is to sell shares worth $35 million to the investor.

Under the terms of the agreement, Zosano Pharma Corp (NASDAQ:ZSAN) is to control the timing and the amount of any investment by LPC. The investor will also be required to make purchases based on the purchase agreement and prevailing market prices at the time of each sale.

Zosano Pharma Corp (NASDAQ:ZSAN) plans to use proceeds from the purchase agreement to fund long-term study of its lead product candidate M207, and for general corporate purposes.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ZSAN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Q3 Financials Highlight Growth

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) gained 4.37% after reporting financial results for the three and nine months ended September 30, 2017. According to their Chief Executive officer, Adrian Adams, performance in the quarter underscore strength in underlying business and growth in the U.S and Canada.

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)

ARLZ Stock Performance

Investors’ confidence on the stock has taken a hit in recent months as seen by the stock trading in a downtrend. Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) is down by more than 50% for the year. It awaits to be seen if the better than expected financial results have what it takes to push the stock higher.

According to Mr. Adams, Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) is on the path to profitability given the performance in third quarter.

“We are delighted with the evolution of Zontivity®, the improved outlook for the Toprol-XL® franchise in the U.S. and the continued strong performance of the Canadian business. As a result of this performance, we updated our 2017 financial guidance and now expect full-year net revenue to be in the range of $95 million to $105 million,” said Mr. Adams.

Aralez Cost Cuts

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) plans to carry out further financial reforms as part of an effort that seeks to accelerate growth heading into the year end. The efforts chould result in a leaner, yet efficient, performance oriented operating model. The improvements are geared towards streaming operations in the U.S with a view of delivering profitability that support growth.

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) plans to trim its Selling, General and Administrative expenses by $32 million or 28%, as part of a cost cutting drive. Expense reductions will include reductions in the amount of money spent on marketing, professional and consulting fees.

Aralez Q3 Financials

Revenues for the three months ended September 30, 2017 totaled $24.3 million nearly double revenues of $13.6 million reported last year. Selling General and Administrative expenses dropped to $24.7 million, from $25.4 million generated in the third quarter of last year.

Net loss in the quarter increased to (-$24.4) million or $0.37 a share, compared to a net loss of (-$20.6) million reported in Q3 2016. Aralez Pharmaceuticals exited the third quarter with cash and cash equivalent of approximately, $40.7 million, sufficient to fund operations over the next 12 months.

Buoyed by the growth phase transition, Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) has revised its full year outlook. The pharmaceutical company now expects revenues of between $95 million and $105 million for the full year, from an initial guidance of between $80 million and $100 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ARLZ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Smart Sand Inc. (NASDAQ:SND)

Smart Sand Inc. (NASDAQ:SND) Revenues Surge 260%

Smart Sand Inc. (NASDAQ:SND)

Shares of Smart Sand Inc. (NASDAQ:SND) gained 15.12% after the low cost producer of high-quality Northern White raw frac sand reported its best-ever quarter. Revenue for the three months ended September 30, 2017, increased 260% year-over-year, due to higher sales volumes and increased freight revenues.

Smart Sand Inc. (NASDAQ:SND)

According to Chief Executive Officer Charles Young, performance in the quarter underscored the company’s focus on maximizing production and effective management of railcar movements.

“Market demand for our high quality, Northern White frac sand remains strong and we look forward to bringing our additional 2.2 million tons of annual production capacity online by the end of the first quarter of 2018,” said Mr. Adams.

The sentiments appear to have strengthened investors’ confidence in the stock as it continues to bounce back from this year’s low. However, Smart Sand is still trading in a downtrend after losing more than 60% in market value since February.

According to data compiled Zacks Investment Research, Smart Sand Inc. (NASDAQ:SND) is currently rated as a ‘strong buy’ by five Wall St. analyst firms.

Smart Sand Q3 Financial Results

Revenues for the three months ended September 30, 2017 totaled $39.3 million. Smart Sand Inc. (NASDAQ:SND) attributes the 260% increase to customers billed through freight charges as well as increased sales volumes. Revenue in the quarter was also up by 32% compared to the second quarter, due to the higher average selling price.

Smart Sand sold a total of 653,400 tons in the quarter representing a 184% year over year increase from 229,600 tons sold last year. The number of tons sold in the quarter also represented a 23% increase from the second quarter.

Smart Sand Inc. (NASDAQ:SND) generated a net income of $7 million or $0.17 a share in the quarter compared to a net loss of (-$0.1) million reported last year. Adjusted EBITDA totaled $11.4 million nearly triple $4.5 million reported during the third quarter of 2016. Smart Sand attributes the increase to increase in sales volume and higher average selling price per ton.

Capital expenditure in the quarter totaled $19.9 million mostly attributed to expansion works at the Oakdale sand processing facility and investment in various enhancement and cost improvement projects.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SND and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.